Healthcare and Pharmaceuticals industry

Global Chronic Kidney Disease Drugs Market Size Share Forecast 2025




 

Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Chronic kidney disease can be controlled and prevented from worsening with the help of kidney friendly diet plans and efficiently managing other diseases, which may lead to chronic kidney diseases. For instance, facts such as maintaining a healthy blood pressure, having a low-salt and low-fat diet, control blood sugar, regular exercise, and avoiding smoking and drinking may prevent chronic kidney disease from worsening. Another form of kidney disease is acute kidney disease, which occurs directly due to disorders affecting kidney such as inadequate blood supply and improper urine flow from kidneys. Apart from medication management, other treatment options for end stage renal diseases include dialysis and kidney transplant.
Market Dynamics
The global chronic kidney disease drugs market is driven by factors such as increasing prevalence of chronic kidney disease and high presence of generic drug manufacturers in the market. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. were estimated to have chronic kidney disease in 2017. Individual government organizations and manufactures are indulged in research and development as well as increasing awareness about chronic kidney diseases, which is fostering growth of the chronic kidney disease drugs market. In March 2018, the Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease. Continuous requirement of medication coupled with easy availability of drugs is expected to boost growth of chronic kidney disease drugs market over the forecast period. However, absence of novel treatment option and delay in diagnosis of the disease due to vague symptoms are expected to hinder growth of the chronic kidney disease drugs market.
Key features of the study:
• This report provides in-depth analysis of chronic kidney disease drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018-2026), considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global chronic kidney disease drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the chronic kidney disease drugs market
Detailed Segmentation:
• Global Chronic Kidney Disease Drugs Market, By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
• Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Chronic Kidney Disease Drugs Market, By Region:
o North America
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o U.S.
o Canada
o Europe
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Latin America
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o Brazil
o Mexico
o Rest of Latin America
o Middle East
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o GCC
o Israel
o Rest of Middle East
o Africa
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o Central Africa
o South Africa
o North Africa
• Company Profiles
o Amgen, Inc.*
o Company Overview
o Product Portfolio
o Financial Performance
o Key Strategies
o Recent Developments
o Teva Pharmaceutical Industries Ltd.
o Pfizer, Inc.
o AstraZeneca Plc
o F. Hoffmann La Roche Ltd.
o Sanofi S.A.
o Kissei Pharmaceutical Co. Ltd.
o AbbVie Inc.
o GlaxoSmithKline Plc
o Keryx Biopharmaceuticals, Inc.
"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Drug Class
o Market Snippet, By Distribution Channel
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o PEST Analysis
o PORTER's Analysis
o Regulatory Scenario
4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o ACE Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o B-Blockers
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Calcium Channel Blockers
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Diuretics
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Erythropoiesis-Stimulating Agents (ESAs)
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
5. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, 2016-2026
o Segment Trends
o Hospital Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Retail Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Online Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
6. Global Chronic Kidney Disease Drugs Market, By Regions, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, By Region, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, For Regions, 2017-2026
o North America
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o U.S.
o Canada
o Europe
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of APAC
o Latin America
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Africa
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o Central Africa
o South Africa
o North Africa
o Middle East
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o GCC
o Israel
o Rest of Middle East
7. Competitive Landscape
o Company Profiles
o Amgen, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Teva Pharmaceutical Industries Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Pfizer, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o AstraZeneca Plc
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o F. Hoffman La Roche Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Sanofi S.A.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Kissei Pharmaceutical Co. Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o AbbVie, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o GlaxoSmithKline Plc
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Keryx Biopharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
8. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 29 market data tables and 47 figures on "Chronic Kidney Disease Drugs Market - Global forecast to 2026".
 



Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.